BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
Number Citing Articles
1 Hahn GD, Golovics PA, Wetwittayakhlang P, Al Khoury A, Bessissow T, Lakatos PL. Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing? Biomedicines 2022;10:749. [DOI: 10.3390/biomedicines10040749] [Reference Citation Analysis]
2 Norton B, Sullivan A, Senior J, Candela N, Jason M, Weyant K. Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2021.12.001] [Reference Citation Analysis]
3 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United European Gastroenterol J 2021;9:398-406. [PMID: 33203339 DOI: 10.1177/2050640620965106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]